Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Informa boss Stephen Carter said: “It is clear that the B2B Market is moving to Operating Scale and Industry Specialisation....
...You Don’t Own Me: How Mattel v....
...The Carter Center’s work against guinea worm, headed by Ruiz-Tiben, has made good progress....
...About 84m people tuned in to watch the showdown between Donald Trump and Hillary Clinton on Tuesday night — surpassing the 1980 matchup between Ronald Reagan and Jimmy Carter, which drew 80.6m to become...
...When Jimmy Carter was diagnosed last year with melanoma that had spread to his brain, many people feared the worst for the oldest living US president....
...It gained publicity after former US president Jimmy Carter hailed it for sending his advanced melanoma into remission....
...Jimmy Carter can tell you why AstraZeneca is contemplating paying $5bn for an unquoted Dutch biotech company with a single product in phase III trials....
...Paul Carter, executive vice-president of Gilead, is candid about the company’s conundrum. “There’s this sort of pressure now we are a $30bn-a-year revenue company,” says Mr Carter....
...At the time, the Carter Center, among other agencies, was in the region combating Guinea worm....
...Now that Abbvie’s £35bn bid for Shire has collapsed and the chances of Pfizer making a fresh £69bn bid for AstraZeneca have greatly diminished, it is also the sector’s biggest potential deal of the year....
...Pyramid scheme Asked whether he could see anything on peering into Tutankhamun’s tomb, Howard Carter breathlessly replied: “Yes! Wonderful things!”...
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...Aged 65, she remains on the board of charitable organisations, including Oxfam in the UK and in the US the Carter Center, a human rights organisation, and the MacArthur Foundation, an educational charity...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Clients include Visa, Pfizer, Verizon Wireless and the American Postal Workers Union....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last month, GlaxoSmithKline took the most striking step with the launch of ViiV Healthcare, a groundbreaking partnership with its rival Pfizer....
...Wisely, Carter reflects that while Nicholas II would have been a fine constitutional monarch in place of George V, it would have taken a truly exceptional autocrat to save tsarist Russia....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...Evercore has advised on several key deals this year, including the $64bn acquisition of Wyeth by Pfizer and the restructuring of General Motors....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
International Edition